基于核酸的策略和纳米技术的应用,用于向治疗
Andrea Patrizia Falanga1, Stefano D'Errico1
1Department of Pharmacy, University of Naples Federico II, via D. Montesano, 49, 80131 Naples, Italy.
核酸疗法,包括RNA干扰 (RNAi) 和反感性寡核酸 (ASO),已经显示出治疗遗传疾病的前景. 这些疗法提供了针对性的基因沉默,为以前无法治疗的疾病提供了新的希望.
科学领域:
- 生物技术是生物技术.
- 分子生物学分子生物学
- 药理学 药理学 是一个学科.
背景情况:
- 自2010年代中期以来,核酸疗法已经成为制药研究的重要领域.
- 像RNA干扰 (RNAi) 和反感性寡核酸 (ASO) 等技术可以实现向基因调制.
- 这些方法为一系列遗传疾病提供了潜在的治疗方法.
研究的目的:
- 审查核酸药物开发领域的进展.
- 突出RNAi和ASO技术的治疗潜力.
- 讨论该领域的挑战和未来方向.
主要方法:
- 临床前和临床研究的文献综述.
- 对药物输送系统和稳定性增强策略的分析.
- 检查基于核酸的药物的监管途径.
主要成果:
- 在开发安全有效的核酸药物方面取得了重大进展.
- 传递系统正在改善,增强细胞吸收并减少非目标效应.
- 几种核酸疗法已获得监管部门的批准,证明了其临床可行性.
结论:
- 核酸治疗药物代表着快速发展和有前途的药物类别.
- 在交付和向方面不断的创新将扩大它们的治疗应用.
- 这些疗法具有治疗各种疾病的潜力,这些疾病的医疗需求尚未得到满足.
更多相关视频
09:04Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
Published on: September 21, 2017
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Microorganisms in Medicine and Therapeutics
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
